
BioCentury
@BioCentury
Followers
16K
Following
4K
Media
884
Statuses
39K
The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: https://t.co/V33Z1gfUfZ
Redwood City, Calif.
Joined December 2010
$GSK's Blenrep gains approvals in Europe and Canada to kick off its comeback story, but will FDA make an example of the ADC in its push for comprehensive dose optimization?
biocentury.com
The latest hurdle for Blenrep’s comeback in the U.S. isn’t the same lack of efficacy that sank its accelerated approval conversion two years ...
0
1
2
Buoyed by a string of exits, Omega Funds expects few changes to its investment strategy as it deploys its new $647M eighth fund
biocentury.com
With little change in its strategy despite challenging market conditions, Omega Funds will have $647 million to deploy from its eighth fund, roughly ...
1
2
2
BioCentury's latest in Management Moves in the life sciences: @NIH funding advocate Mary Woolley to step down. Plus: Galapagos continues to remake C-suite and a new CEO for Tenvie
biocentury.com
Mary Woolley, the face of biomedical research advocacy in Washington for more than three decades, announced she will step down as president and CEO of Rese...
0
0
2
In BioCentury's Venture Report: Australia's Brandon Capital closed its sixth fund at A$439M, far outsizing the firm's previous vehicles; plus Dispatch's $216M launch and more
biocentury.com
Brandon Capital has closed its sixth fund at A$439 million, far above the A$350 million goal it had set and more than 75% larger than its A$...
0
0
1
BioCentury's latest biopharma management moves: Kristin Yarema to lead merged Inmagene-Ikena entity. Plus: Ipsen names trio of EVPs
biocentury.com
Ahead of the planned closing of a deal that would unite Inmagene Biopharmaceuticals Co. Ltd. with Ikena Oncology Inc. (NASDAQ:IKNA), the organizations ha...
0
0
2
Asia deals: Globalization is open for business. An analysis of 198 Asia deals in the last 2.5 years finds Western biotechs are engaging even more than pharmas. A breakdown of deal values, therapeutic areas, modalities and first-in-class potential.
biocentury.com
Dealmaking in Asia has been a bright spot in 2025, as the maturation of biotech in China converges with Western demand for innovative assets and — a...
0
0
0
Abivax’s miRNA therapy emerges as a new mechanism for ulcerative colitis. Plus: Roche misses in pair of Ph III trials for COPD, and updates from Alkermes, Diamedica, and more, in BioCentury’s Clinical Report.
biocentury.com
One stock posted a large, data-driven gain in a week of little market reaction to clinical readouts, with Abivax’s first-in-class miRNA therapy demo...
0
0
2
Concentra's deal for iTeos is at least the sixth acquisition the firm has made since April, providing an off-ramp for struggling biotechs
biocentury.com
Concentra, the Tang Capital-backed entity that acquires and shuts down struggling biotechs, made at least its sixth deal this year by agreeing to buy Iteos...
0
0
2
Prasad to oversee @US_FDA Commissioners Priority Voucher Program; his role among handful of new details on pilot program
biocentury.com
Companies may now apply to receive one of up to five new FDA priority review vouchers designed to streamline reviews of innovative drugs under a pilot prog...
0
0
1
With a CRL disclosed Tuesday, Replimune became the latest biotech to say an FDA review decision conflicted with the signals the agency had been sending under prior leadership
biocentury.com
Shifting FDA standards may be making the path to market less predictable for biotechs. One more company professed surprise Tuesday at receiving a complete ...
0
0
0
BioCentury's latest biopharma Management Moves: Steve Bates, longtime head of BIA, named executive chair of U.K.’s Office of Life Sciences. Plus: Novartis names Mazuk chief patient experience officer and updates from Seres and ABPI
biocentury.com
The U.K. government has named Steve Bates executive chair for the Office of Life Sciences. He has tendered his resignation as CEO of the U.K.’s BioI...
0
0
2
Sanofi is buying vaccine technology company Vicebio for $1.15B up front, soon after the emergence of early data from a clinical study of the start-up's first product
biocentury.com
Early data emerging from a clinical study of the first product derived from Vicebio’s vaccine platform have spurred Sanofi’s decision to acqu...
0
0
2
BioCentury's latest management moves column: Nodthera names Jyothis George CMO. Plus: Updates from Protalix, Medigene
biocentury.com
Nodthera Ltd., a developer of NLRP3 programs to treat obesity and inflammatory disorders, named Jyothis George CMO. George was global medical VP for obesi...
0
0
1
New @US_FDA CDER Director Tidmarsh is taking over an agency in crisis. The media will focus on his controversial COVID comments, but industry wants to know if he can right the ship.
0
1
0
As @Sarepta loses platform designation, the @US_FDA pathway’s future is uncertain. #GeneTherapy #FDA $SRPT
biocentury.com
The first platform technology designation issued by FDA has been revoked, validating earlier concerns about its issuance and raising questions about whethe...
0
2
3
.@US_FDA Commissioner Makary says he is convinced an mRNA vaccine killed friend's father. Will his embrace of anecdotal evidence extend beyond COVID?
biocentury.com
Recent public comments by FDA Commissioner Marty Makary have endorsed a broader role for anecdotal evidence in shaping regulatory decisions. While the stat...
0
0
0